No Data
Express News | Zhejiang Jiuzhou Pharmaceutical signed a global strategy cooperation agreement with the School of Pharmacy at Fudan University.
Express News | Zhejiang Jiuzhou Pharmaceutical: Wholly-owned subsidiary passed the United Kingdom GMP certification.
Express News | Zhejiang Jiuzhou Pharmaceutical: Controlling subsidiary obtains pharmaceutical registration certificate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) subsidiary obtained the registration certificate for dopamine hydrochloride injection pharmaceutical.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company's controlling subsidiary, Nanjing Kangchuanji Medical Technology Co., Ltd. ...
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Dopamine Hydrochloride Injection obtained the pharmaceutical registration certificate.
Gelonghui October 31st, zhejiang jiuzhou pharmaceutical (603456.SH) announced that its holding subsidiary Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. (referred to as 'Kangchuanji Pharmaceutical') has received the 'Drug Registration Certificate' for Dopamine Hydrochloride Injection issued by the National Medical Products Administration (Acceptance Number: CYHS2301483). Dopamine Hydrochloride Injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxemia, cardiac surgery, renal failure, congestive heart failure, etc.; especially for shock with oliguria and normal or low peripheral vascular resistance, where shock persists after volume resuscitation.
Zhejiang Jiuzhou Pharmaceutical (603456): Q3 revenue decline narrows month-on-month, CDMO gross margin remains stable
In the first three quarters of 2024, the company's revenue declined somewhat due to the impact of CDMO projects and intensified competition in the active pharmaceutical ingredient sector. Profits also decreased significantly due to the decline in gross margin and the impact of exchange gains and losses on interest income during the same period.
No Data
No Data